Obinutuzumab in Chronic Lymphocytic Leukemia: Design, Development and Place in Therapy

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s104869
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Real World Outcomes of Obinutuzumab Monotherapy in Patients With Chronic Lymphocytic Leukemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2019English

Update on Therapy of Chronic Lymphocytic Leukemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

Acalabrutinib With Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3-Year Follow-Up

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma and Exposure–Response in CLL

CPT: Pharmacometrics and Systems Pharmacology
ModelingSimulationCardiovascular MedicinePharmacologyCardiology
2014English

Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab Into Clinical Practice

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Chronic Lymphocytic Leukemia in Pregnancy

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2000English

Anticoagulant Therapy in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Accelerating CAR Therapy in CLL: The Development and Challenges of CAR T Cell Therapy for Chronic Lymphocytic Leukemia

American Journal of Hematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy